MoonLake Immunotherapeutics (MLTX) Preferred Shares (2021)
MoonLake Immunotherapeutics' (MLTX) quarterly Preferred Shares came in at $72466.0 in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Preferred Shares (2021) Analysis & Trends
MoonLake Immunotherapeutics' Preferred Shares history runs 1 years deep, the most recent figure standing at $72466.0 for Q4 2021.
- On a quarterly basis, Preferred Shares changed N/A year-over-year to $72466.0 in Q4 2021; TTM through Dec 2021 was $72466.0, a N/A change from a year earlier, with the FY2021 full-year figure at $72466.0, changed N/A from the prior year.
- Preferred Shares was little changed at $72466.0 in Q4 2021 per MLTX's latest filing.
- Across five years, Preferred Shares topped out at $72466.0 in Q4 2021 and bottomed at $72466.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn | - |
| 10 | MoonLake Immunotherapeutics | 1.42 Bn | 1.06 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 72,466.00 |